RHHBF - Roche Holding AG

Is Novo Nordisk (NVO) Stock Outpacing Its Medical Peers This Year?

Here is how Novo Nordisk (NVO) and Roche Holding AG (RHHBY) have performed compared to their sector so far this year.

• 
  Are Consumer Discretionary Stocks Lagging DraftKings (DKNG) This Year?

  Zacks
• 
  Are Construction Stocks Lagging North American Construction Group (NOA) This Year?

  Zacks

Zacks Industry Outlook Highlights Eli Lilly, Johnson & Johnson, Novo Nordisk, Roche and Novartis

Eli Lilly, Johnson & Johnson, Novo Nordisk, Roche and Novartis have been highlighted in this Industry Outlook article.

Exclusive-Roche looking to sell or shut down California biologic drug plant

Swiss drugmaker Roche Holding AG plans to sell its 800-employee drug manufacturing plant in Vacaville, California, or it will shut the factory by 2029, according to e-mailed letters to workers seen by Reuters on Wednesday. In a statement, Roche confirmed the divestiture plan for the site, which makes monoclonal antibodies from genetically modified living cells, but did it not address the potential closing of the plant or its timeline. It also plans to focus on drugs targeting smaller patient populations moving forward and to draw on a range of biotechnology methods beyond monoclonal antibodies, it said, adding there would be no impact to operations or employees at this time.

5 Large Drug Stocks to Watch From a Thriving Industry

Drug/biotech companies are likely to see significant advances in innovation in 2023. In the Large-Cap Pharmaceuticals industry, Eli Lilly (LLY), J&J (JNJ), Novo Nordisk (NVO), Roche (RHHBY) and Novartis (NVS) are worth retaining in your portfolio.

Kodiak (KOD) Advances With Tarcocimab Amid Stiff Competition

Kodiak (KOD) focuses on completing ongoing studies on tarcocimab for several retinal indications. However, competition in the market and the lack of other candidates in the pipeline are concerns.

Sarepta (SRPT) Down 11% on FDA Extending DMD Gene Therapy Review

The FDA extends the review period for Sarepta's (SRPT) BLA for DMD gene therapy by almost four weeks to Jun 22. The agency may limit the use of the therapy in children aged between four and five.

Why Shares of Rain Oncology Are Plummeting Today

Shares of Rain Oncology (NASDAQ: RAIN) were down 87% Monday afternoon after the precision oncology company released top-line results for its lead therapy, milademetan, to treat dedifferentiated liposarcoma, a type of cancer affecting fatty tissue, usually in the arms and legs. Rain said that milademetan, an inhibitor of the MDM2-p53 complex that reactivates p53, a known tumor inhibitor, taken orally, did not meet its primary endpoint of efficacy in a phase 3 trial to treat patients with dedifferentiated (DD) liposarcoma (LPS). Based on the disappointing results, Rain said it does not plan to pursue further development of the therapy to treat DD LPS.

Regeneron (REGN) Faces Challenges as Eylea Sales Decline

Regeneron (REGN) loses some of its gains as sales of its lead drug, Eylea, decline. Nevertheless, Dupixent sales boost the top line.

Pharma Stock Roundup: FDA Nod to ABBV's Rinvoq for New Indication & Other Updates

FDA panel votes in favor of Pfizer's (PFE) experimental maternal RSV vaccine. FDA approves AbbVie's (ABBV) Rinvoq for Crohn's Disease.

Roche's (RHHBY) MS Drug Meets Goals in the Phase II Study

Roche's (RHHBY) investigational oral fenebrutinib meets its primary and secondary endpoints in the phase II FENopta study.

Sarepta's (SRPT) DMD Gene Therapy Gets Endorsed by FDA Panel

The FDA's CTGTAC narrowly recommends granting accelerated approval to Sarepta's (SRPT) DMD gene therapy. A final decision from the agency is expected by the end of this month.

Pharma Stock Roundup: BAYRY Mixed Q1 Results, AZN, RHHBY Regulatory/Pipeline Updates

Bayer (BAYRY) announces mixed Q1 results. AstraZeneca's (AZN) Ultomiris gets approval for a new rare disease indication in the EU.

Halozyme (HALO) Q1 Earnings Disappoint, Revenues Rise Y/Y

Halozyme (HALO) first-quarter earnings and revenues miss estimates. The company reiterates its guidance for 2023.

Sarepta (SRPT) Q1 Earnings Beat Estimates, Revenues Up Y/Y

Sarepta (SRPT) delivers narrower-than-expected loss per share in first-quarter 2023. Total revenues beat estimates on the back of strong product sales growth during the quarter.

Roche (RHHBY) Q1 Revenues Decline on Lower COVID-19 Test Sales

Roche's (RHHBY) performance in first-quarter 2023 is pretty ho-hum as COVID-19-test sales continue to decline.

Roche Q1 sales decline tempered by swift uptake of new eye drug

(Reuters) -Switzerland's Roche said first-quarter sales dropped 7% on falling demand for its COVID-19 therapies and tests, less steep than analysts had expected thanks to strong revenue growth from a new eye drug. Group revenue fell to 15.3 billion Swiss francs ($17.2 billion), the company reported on Wednesday, beating a market view of 14.8 billion francs on a strong launch of anti-blindness treatment Vabysmo and better-than-expected sales of COVID antibody treatment Ronapreve. The company, which does not report earnings for its first quarter, reiterated that pandemic-related sales - mainly lab testing, Ronapreve and repurposed arthritis drug Actemra - would drop by 5 billion francs this year.

Roche (RHHBY) Polivy Combination for DLBCL Gets Full Approval

Roche (RHHBY) gets full approval for Polivy (polatuzumab vedotin-piiq) in combination with Rituxan, cyclophosphamide, doxorubicin and prednisone (R-CHP) for the treatment of adult patients who have previously untreated DLBCL.

Roche (RHHBY) Announces Data on Tecentriq Combo for HCC

Roche's (RHHBY) new data from the late-stage IMbrave050 study reveals that the combination of Tecentriq and Avastin reduces the risk of cancer relapsing in people with certain types of adjuvant liver cancer in a phase III study.

Sarepta Down on Reports of FDA Almost Rejecting DMD Gene Therapy

Per a Stat News article, the FDA initially considered rejecting Sarepta's (SRPT) regulatory filing seeking FDA's accelerated approval for DMD gene therapy.

Medical research has driven 'the last 200 years of economic expansion': Michael Milken

Health investment and innovation has been on a roller coaster as a result of the pandemic. But the momentum needs to continue, according to Michael Milken.

Pfizer (PFE) Gets FDA Acceptance for Braftovi + Mektovi sNDAs

FDA accepts Pfizer's (PFE) sNDAs seeking approval of Braftovi + Mektovi for BRAF V600E-mutant non-small cell lung cancer.

J&J (JNJ) Offers $8.9B Settlement for Talc Cancer Lawsuits

To completely resolve its cosmetic talc litigation, J&J (JNJ) offers a settlement amount of $8.9 billion payable over a period of 25 years.

The Zacks Analyst Blog Highlights Berkshire Hathaway, Roche Holding, Thermo Fisher Scientific, Mitsubishi UFJ Financial Group and Synopsys

Berkshire Hathaway, Roche Holding, Thermo Fisher Scientific, Mitsubishi UFJ Financial Group and Synopsys are included in this Analyst Blog.

Roche's Slow Growth Shouldn't Drive Investors Away

Swiss pharmaceutical company Roche (OTC: RHHBY) took a hit from a decline in sales of COVID-19 diagnostic and treatment products in 2022, with group sales inching up 2% at constant exchange rates (CER) to 63.28 billion Swiss francs ($68.34 billion). The company's pharmaceutical and diagnostic divisions were both affected, and net income came in at 13.5 billion francs ($14.6 billion), a decline of 6% compared to 2021 under international financial reporting standards (IFRS). The company expects "the sharp decline in sales of COVID-19 products" to continue through 2023, leading sales to decrease "in the low single digit range," although it also expects its sales of other products to show strong growth.